IL13RA2 Antikörper

Produktnummer ABIN1383686

Es sind 8+ Publikationen für dieses Produkt verfügbar. Der Maus Monoklonal anti-IL13RA2 Antikörper wird verwendet zum Nachweis von IL13RA2 in Proben von Human. Er wurde validiert für ELISA, IHC und FACS.

Kurzübersicht für IL13RA2 Antikörper (ABIN1383686)

Target: IL13RA2 (Interleukin 13 Receptor, alpha 2 (IL13RA2))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser IL13RA2 Antikörper ist unkonjugiert

Applikation: ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS)

Klon: B-D13

Produktdetails anti-IL13RA2 Antikörper

Spezifität: Recognises the IL-13 receptor a2 (IL-13 Ra2), a 44 kDa protein

Aufreinigung: Ion exchange chromatography

Sterilität: 0.22 μm filtered

Immunogen: IL-13Ra2 transfected CHO cell line,Myeloma X63/AG.8653 x Balb/c spleen cells

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Phosphate-buffered saline. Sterile-filtered through 0.22 μm. Carrier and preservative free

Konservierungsmittel: Without preservative

Lagerung: 4 °C

Informationen zur Lagerung: Stable at +2-8°C for 12 months. For longer storage freeze aliquots.

Referenzen für anti-IL13RA2 Antikörper (ABIN1383686)

Kawakami, Terabe, Kioi, Berzofsky, Puri: "Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 12, Issue 15, pp. 4678-86, (2006) (PubMed).

Kawakami, Kawakami, Puri: "Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease." in: Molecular cancer therapeutics, Vol. 3, Issue 2, pp. 137-47, (2004) (PubMed).

Blanchard, Durual, Estienne, Bouzakri, Heim, Blin, Cuber: "IL-4 and IL-13 up-regulate intestinal trefoil factor expression: requirement for STAT6 and de novo protein synthesis." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 172, Issue 6, pp. 3775-83, (2004) (PubMed).

Kawakami, Kawakami, Kasperbauer, Hinkley, Tsukuda, Strome, Puri: "Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 9, Issue 17, pp. 6381-8, (2003) (PubMed).

Joshi, Kawakami, Leland, Puri: "Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 8, Issue 6, pp. 1948-56, (2002) (PubMed).

Lordan, Bucchieri, Richter, Konstantinidis, Holloway, Thornber, Puddicombe, Buchanan, Wilson, Djukanović, Holgate, Davies: "Cooperative effects of Th2 cytokines and allergen on normal and asthmatic bronchial epithelial cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 169, Issue 1, pp. 407-14, (2002) (PubMed).

Kawakami, Kawakami, Puri: "IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 169, Issue 12, pp. 7119-26, (2002) (PubMed).

Joshi, Plautz, Puri: "Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas." in: Cancer research, Vol. 60, Issue 5, pp. 1168-72, (2000) (PubMed).

Details zu IL13RA2

Target: IL13RA2 (Interleukin 13 Receptor, alpha 2 (IL13RA2))

Andere Bezeichnung: CD213a2

Hintergrund: IL-13Ra2

Molekulargewicht: 74 kDa